Mmm, closing at the daily low is never good. Would be reasonable to expect this to move closer toward its cap raise price of 1.25c over the next week or two.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
